Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma--reassessment based on the revised Japanese national insurance reimbursement system.
D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000191:economics* / Q000453:epidemiology; D003362:Cost-Benefit Analysis / Q000379:methods* / Q000706:statistics & numerical data; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000191:economics*; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics / Q000706:statistics & numerical data; D007564:Japan / Q000453:epidemiology; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000191:economics / Q000453:epidemiology; D008297:Male; D017059:Models, Econometric; D009313:National Health Programs / Q000191:economics / Q000706:statistics & numerical data; D015995:Prevalence; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014055:Tomography, Emission-Computed / Q000191:economics* / Q000706:statistics & numerical data*; D014915:Whole-Body Counting / Q000191:economics / Q000706:statistics & numerical data
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18